2024-03-28T14:49:55Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02015793
2022-10-31T07:44:37Z
1642838163960:1642838198944:1642838233003:1642838242511
1642838403551:1642838412624
[原著]再発悪性グリオ-マに対するIFN-β局所投与とACNU動注療法の試み
Combined Treatment of Local Injection IFN-β and Intracarotid Injection of ACNU to Recurrent Malignant Gliomas
仲宗根, 進
六川, 二郎
高良, 英一
銘苅, 晋
石川, 泰成
久田, 均
Nakasone, Susumu
Mukawa, Jiro
Takara, Eiichi
Mekaru, Susumu
Ishikawa, Yasunari
Kuda, Hitoshi
Five cases of recurrent malignant gliomas were treated with local injection of interferon- βcombined with intracarotid injection of 1-(4-amino 2methy1-5-pyrimidinyl)methy1 -3-(2-chlor∝thy1)-3-nitrosourea hydrochloride(ACNU). All patients had been already treated with intravenous injection of IFN-β and/or ACNU as well as conventional radiotherapy after surgery. IFN-β(3×10^6 IU, 3 times a week) was locally injected through a catheter placed into tumor-removed cavity. ACNU (100mg/6weeks) was injected into the carotid artery following osmotic blood brain barrier modification produced by arterial injetion of 20% 200ml mannitol. Multiple intracranial lesions were checked with contrast enhanced CT in all cases. None of the cases exhibited clinical regression. But three of them showed tumor regression around the IFN-β injected cavity, although the other part of the tumor remained progressive. These results suggested that direct tumorddal effects of IFN-β was exhibited to recurrent malignant gliomas, and local injection of IFN-β is so useful that should be used from the initial stage in addition to its intravenous use. There should be some strategic ideas to overcome ACNU resistance when reused.
論文
http://purl.org/coar/resource_type/c_6501
琉球大学医学部
Faculty of Medicine, University of the Ryukyus
1991
VoR
0289-1530
AN10027430
琉球大学医学会雑誌 : 医学部紀要 = Ryukyu medical journal
3-4
11
140
131
jpn
open access
琉球医学会